evans blue has been researched along with tacrolimus in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Furuichi, Y; Maeda, M; Matsuoka, N; Mutoh, S; Noto, T; Yoneda, Y | 1 |
2 other study(ies) available for evans blue and tacrolimus
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Tacrolimus (FK506) suppresses rt-PA-induced hemorrhagic transformation in a rat thrombotic ischemia stroke model.
Topics: Animals; Blood-Brain Barrier; Brain; Endothelial Cells; Evans Blue; Immunohistochemistry; Immunosuppressive Agents; Infarction, Middle Cerebral Artery; Male; Microvessels; Platelet Endothelial Cell Adhesion Molecule-1; Rats; Rats, Inbred SHR; Recombinant Proteins; Tacrolimus; Tissue Plasminogen Activator | 2009 |